CommercialCoverageMedium impact
09.00.17q, Intensity-Modulated Radiation Therapy (IMRT) (Independence Administrators)
Independence Blue Cross·Radiation Oncology, Oncology·Medical Policy
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued IMRT policy 09.00.17q with an annual review update (version 09.00.17r now supersedes it). Key coverage expansions include esophageal and small/non-small cell lung cancers now classified as medically necessary, and clarified IMRT criteria for breast, lung, and thymoma/thymic cancers. The policy applies only to groups NOT enrolled in the UM vendor program; affected groups should verify applicability at renewal.
Action Required
REQUIREMENTS:
- Immediately: Billing team must verify which Independence Administrators groups are subject to this policy (excludes UM vendor program enrollees). Contact plan administrator to confirm applicability for each account.
- Before next claim submission: Update billing system documentation to reflect expanded IMRT medical necessity coverage for esophageal cancer, small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) diagnoses. These are now covered when medically necessary criteria are met.
- Update provider/clinical documentation templates to ensure IMRT justification for breast, lung, and thymoma/thymic cancers specifically addresses the clarified criteria (target volume proximity to critical structures, dose constraints, prior irradiation, concave/convex geometry, dose escalation, or toxicity reduction >15%).
- For all IMRT claims: Ensure diagnosis codes clearly document the specific cancer type and that at least one medical necessity criterion is met per policy. Without proper documentation, claims may be denied.
- Note: IMRT is excluded from capitated radiology programs and eligible for separate reimbursement—do not apply capitation to these codes (77280, 77285, 77290, 77293, 77295, 77300).